SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH H impact

IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization

Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting® 2026 an

IPSEY

Related stories